Latest Content

CDK4/6 Inhibitor Combos Miss Survival Goal in Metastatic Breast Cancer Subset

December 12th 2024, 8:43pm

By Morgan Bayer

Article

No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations during initial treatment for HR-positive, HER2-negative metastatic breast cancer.

Ultra-Sensitive ctDNA Testing Can Detect ctDNA in HR+ Breast Cancer

December 12th 2024, 7:00pm

By Ashley Chan

Article

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

My Need for A Disciplined Mind as a Cancer Survivor

December 12th 2024, 6:00pm

By Brian Sluga

Article

For many years, I have trained my mind to have more discipline, especially after being diagnosed with testicular cancer in my 20s.

Time to Next Treatment Slightly Higher With Orserdu in Breast Cancer Subset

December 12th 2024, 4:00pm

By Spencer Feldman

Article

In certain patients with ESR1-mutant breast cancer, time to next treatment was slightly higher with Orserdu versus PFS in a phase 3 trial.

Older Patients With Early Breast Cancer May Have Worse Immune Side Effects

December 12th 2024, 1:55pm

By Ashley Chan

Article

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune checkpoint inhibitors.

Imlunestrant-Based Therapy May Improve Survival Without Progression in Advanced Breast Cancer

December 11th 2024, 11:00pm

By Chris Ryan

Article

Treatment with imlunestrant either with or without Verzenio was shown to improve progression-free survival in some with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

Local Recurrence Lowered With Immediate Surgery in Elderly Patients With Breast Cancer

December 11th 2024, 10:30pm

By Russ Conroy

Article

Receiving immediate surgery was associated with a reduction in local recurrence of breast cancer in elderly patients versus delaying surgery.

Lynparza Continues to Benefit in BRCA1/2+, HER2- Breast Cancer

December 11th 2024, 9:30pm

By Jason M Broderick

Article

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Enhertu Improves Progression-Free Survival in HR+, HER2-Low/Ultralow Metastatic Breast Cancer

December 11th 2024, 8:34pm

By Caroline Seymour

Article

Data from the phase 3 DESTINY-Breast06 trial were presented during the 2024 San Antonio Breast Cancer Symposium.

With CLL, I Try to Make the Best of Everything

December 11th 2024, 6:00pm

By Chester Freeman

Article

I haven’t been too happy with my blood work with CLL, but I try to enjoy what I can — including apples during fall.

Camizestrant Plus Kisqali May Be Safe, Effective in ER+/HER2- Breast Cancer

December 11th 2024, 4:22pm

By Alex Biese

Article

Findings from the phase 1 SERENA-1 study were presented at the 2024 San Antonio Breast Cancer Symposium.

Treatment Discontinuations Reduced With Jaypirca in CLL, SLL

December 11th 2024, 2:33pm

By Tony Berberabe, M.P.H.

Article

Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients with previously treated CLL or SLL.

Survival Outcomes Not Improved With Autologous Stem Cell Transplant in MCL

December 11th 2024, 1:11am

By Gina Mauro

Article

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

Looking Ahead After Kisqali’s FDA Approval for Adjuvant Treatment of Early Breast Cancer

December 10th 2024, 9:57pm

By Darlene Dobkowski, MA

Article

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant setting with early breast cancer.

Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma

December 10th 2024, 8:48pm

By Kristi Rosa

Article

Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.